Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Fugelli

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|December 25, 2002
Eletriptan PfizerPaul J L M Strijbos, Andrew A Parsons, Anders Fugelli
Frontiers in Pharmacology|August 5, 2022
DYRK1a Inhibitor Mediated Rescue of <i>Drosophila</i> Models of Alzheimer's Disease-Down Syndrome PhenotypesBangfu Zhu, Tom Parsons, Wenche Stensen, et al.
Antimicrobial Agents and Chemotherapy|October 22, 2014
LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureusAnna C Nilsson, Håkan Janson, Hedda Wold, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2012
In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureusLouis D Saravolatz, Joan Pawlak, Leonard Johnson, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromeWenche Stensen, Ulli Rothweiler, Richard Alan Engh, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|December 25, 2002
Eletriptan PfizerPaul J L M Strijbos, Andrew A Parsons, Anders Fugelli
Frontiers in Pharmacology|August 5, 2022
DYRK1a Inhibitor Mediated Rescue of <i>Drosophila</i> Models of Alzheimer's Disease-Down Syndrome PhenotypesBangfu Zhu, Tom Parsons, Wenche Stensen, et al.
Antimicrobial Agents and Chemotherapy|October 22, 2014
LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureusAnna C Nilsson, Håkan Janson, Hedda Wold, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2012
In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureusLouis D Saravolatz, Joan Pawlak, Leonard Johnson, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromeWenche Stensen, Ulli Rothweiler, Richard Alan Engh, et al.
Pageof 1